With direct letters, regulatory comments and other activities, Vizient strives to form constructive relationships with lawmakers, regulatory agencies and administration officials, to provide a unified voice on issues that have a direct impact on our members.
2026 Advocacy
- January 6 - Vizient comments to the Partnership for Quality Management (P4QM) on the 2025 Measures Under Consideration (MUC) List
- January 6 - Vizient comments to the Food and Drug Administration (FDA) on draft guidance for industry, “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies”
Connect with Vizient to help you solve health care’s biggest challenges